Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.

"Conflicts of Interest : M. Stewart, M. Hopps, S. Fallet, and L. Amass are employees of Pfizer Inc. M. F. Botteman and A. S. Chopra are employees of Pharmerit International, which received funding from Pfizer Inc. for study design, execution, analysis, and manuscript development. J. A. Carter is an independent scientific consultant who was funded by Pharmerit International. H. H. Schmidt and M. Waddington‐Cruz were investigators for the study and were not financially compensated for collaborative efforts on publication‐related activities. H. H. Schmidt has received support from FoldRx Pharmaceuticals (acquired by Pfizer Inc. in October 2010), Pfizer, IONIS, and Alnylam as a clinical investigator. M. Waddington‐Cruz has received support from FoldRx Pharmaceuticals as a clinical investigator, has served on the scientific advisory board of Pfizer Inc., has received funding from Pfizer Inc. for scientific meeting expenses (travel, accommodations, and registration), has received research support from the National Institutes of Health, and currently serves on the THAOS (Transthyretin Amyloidosis Outcomes Survey) scientific advisory board."

"Funding : This research was supported by Pfizer Inc."